Mashup Score: 1
American Society of HematologyKey Points. Concurrent APVD was safe and effective in untreated HL without clinically significant treatment delays.CR rates by PET were lower than expected at a
See more from The Fellow on Call: The Heme/Onc Podcast
ASCO23 Plenary Session looking at Nivo-AVD vs. BV-AVD is going to change the landscape for Hodgkin’s Lymphoma. Here are results for a phase II on Pembro-AVD (APVD). We need to move past interim PET and move towards ct-DNA!
TFOC Takeaways:
– Incredible PFS at 2 years: 97%
– Interim PET2 negative: only 57%
– EOT PET negative: only 87%
– None of the patients with ct-DNA cleared had relapse regardless of PET results